PDF Cover

Voxelotor Market

The market for Voxelotor was estimated at $62.6 million in 2025; it is anticipated to increase to $107 million by 2030, with projections indicating growth to around $184 million by 2035.

Report ID:DS1802038
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Voxelotor
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Voxelotor Market Outlook

Revenue, 2025

$62.6M

Forecast, 2035

$184M

CAGR, 2026 - 2035

11.4%

The Voxelotor industry revenue is expected to be around $69.8 million in 2026 and expected to showcase growth with 11.4% CAGR between 2026 and 2035. Building on this growth trajectory, the vutrisiran industry is gaining strong strategic importance within the rare disease therapeutics and RNA interference drug markets. Increasing clinical recognition of transthyretin amyloidosis and expanding diagnostic capabilities are significantly improving patient identification rates, which supports wider adoption of disease-modifying therapies. Healthcare systems are also prioritizing innovative treatments that target the underlying cause of genetic disorders rather than managing symptoms alone. Additionally, supportive regulatory frameworks for orphan drugs and growing investments in precision medicine are accelerating commercialization of RNAi-based therapeutics. Pharmaceutical companies are strengthening patient support programs, specialist treatment networks, and reimbursement negotiations to improve market access. As awareness among cardiologists and neurologists increases, particularly in developed healthcare systems, demand for targeted gene-silencing therapies continues to expand, reinforcing the market’s long-term commercial relevance.

Vutrisiran is an RNA interference therapeutic designed to reduce the production of transthyretin protein in the liver, addressing the root cause of transthyretin amyloidosis. The therapy is primarily used to treat hereditary transthyretin amyloidosis with polyneuropathy and is increasingly being adopted for transthyretin amyloid cardiomyopathy treatment. Its key advantage lies in its targeted gene-silencing mechanism and convenient dosing schedule, which improves patient adherence compared to earlier treatment options. Major applications include rare neurological disease management, cardiomyopathy treatment, and precision medicine programs within specialty healthcare centers. Recent market trends include expanding clinical indications, increased investment in RNAi drug platforms, and growing collaboration between biotechnology companies and rare disease research institutions. Furthermore, improvements in genetic screening technologies and the establishment of specialized amyloidosis treatment centers are helping drive demand for advanced therapies such as vutrisiran across global healthcare markets.

Voxelotor market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Voxelotor Market Outlook

Market Key Insights

  • The Voxelotor market is projected to grow from $62.6 million in 2025 to $184 million in 2035. This represents a CAGR of 11.4%, reflecting rising demand across Sickle Cell Disease Treatment, Pharmaceutical Sector, and Clinical Trials.

  • Pfizer Inc. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Canada are the top markets within the Voxelotor market and are expected to observe the growth CAGR of 8.3% to 12.0% between 2025 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 10.9% to 14.3%.

  • The complete eco-system of the Voxelotor market is becoming more attractive for investment due to transitions such as Transition from Conventional Symptom Management to Targeted Hemoglobin Modulation Therapies. These changes are expected to create a positive cycle that supports growth and adds an estimated $5 million in value between 2026 and 2030.

  • The Voxelotor market is set to add $122 million between 2025 and 2035, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rising global prevalence of sickle cell disease and expanding access to specialized hematology care, and

    Advancements in hemoglobin modulation therapies transforming treatment strategies for genetic blood disorders, Voxelotor market to expand 194% between 2025 and 2035.

voxelotor market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Voxelotor - Country Share Analysis

Opportunities in the Voxelotor

Strategic collaborations between biotechnology companies, academic research institutions, and pharmaceutical firms are creating opportunities to advance hemoglobin modulation therapies similar to voxelotor. These partnerships focus on improving drug efficacy, exploring combination therapies, and developing safer treatment alternatives targeting hemoglobin polymerization. Increasing investment in hematology research is also encouraging innovation in disease modifying therapies for genetic blood disorders. The clinical research and drug development segment is expected to benefit significantly from these collaborations. Research hubs in the United States and Europe are particularly active in developing next generation therapies that build upon the molecular targeting approach introduced by voxelotor.

Growth Opportunities in North America and Europe

North America has historically been a key region for the voxelotor market due to the relatively high prevalence of sickle cell disease and strong healthcare infrastructure supporting rare disease treatment. The United States accounts for the majority of regional demand, supported by advanced hematology care networks, specialized treatment centers, and strong awareness programs for genetic blood disorders. Government initiatives encouraging newborn screening and early diagnosis have also played an important role in identifying eligible patients. One major opportunity in this region lies in expanding research and development for next generation sickle cell therapies that build upon hemoglobin modulation strategies. Biotechnology companies and academic institutions are actively collaborating to explore improved treatment approaches and combination therapies. However, competition is increasing as pharmaceutical companies invest heavily in innovative gene therapies and disease modifying treatments for sickle cell disease. These emerging alternatives are reshaping the treatment landscape, prompting healthcare providers to prioritize therapies with stronger long term outcomes and safety profiles within the North American rare disease pharmaceutical sector.
Europe represents an evolving market for voxelotor related therapies, supported by growing awareness of sickle cell disease and strengthening rare disease healthcare frameworks. Countries such as the United Kingdom, France, Germany, and Italy have been expanding specialized hematology services and rare disease treatment programs, which historically supported demand for advanced sickle cell therapies. Increased migration from regions with higher sickle cell prevalence has also contributed to greater focus on screening and disease management across European healthcare systems. A key opportunity in this region lies in the development of new targeted treatments and genetic therapies addressing hemoglobin disorders. Research institutions and biotechnology companies across Europe are investing in innovative treatment platforms aimed at improving disease outcomes. At the same time, the market faces rising competition from emerging curative therapies and alternative pharmacological treatments. Regulatory scrutiny and cost effectiveness evaluations by national healthcare agencies also influence adoption patterns, shaping the long term dynamics of the sickle cell therapeutics market across Europe.

Market Dynamics and Supply Chain

01

Driver: Rising global prevalence of sickle cell disease and expanding access to specialized hematology care

The growing global burden of sickle cell disease is also a major driver for the voxelotor market. SCD remains one of the most common inherited blood disorders, particularly prevalent in regions such as sub-Saharan Africa, the Middle East, and parts of the United States. Increasing patient identification through newborn screening programs and improved diagnostic capabilities has also significantly expanded the number of individuals eligible for disease-modifying therapies. This trend is also creating sustained demand for advanced treatments that address the underlying pathology of hemoglobin polymerization. Alongside rising prevalence, expanding access to specialized hematology care is also further supporting market growth. Healthcare systems are also establishing dedicated sickle cell treatment centers and multidisciplinary care programs that improve disease monitoring and treatment adoption. These specialized care frameworks allow physicians to integrate therapies such as voxelotor into long-term treatment plans, improving patient outcomes while strengthening demand for innovative hemoglobin-targeting drugs.
Technological progress in hemoglobin modulation therapies is also another key driver accelerating the adoption of voxelotor. Unlike conventional treatments that mainly focus on symptom control, voxelotor directly targets hemoglobin polymerization, addressing a central mechanism responsible for sickling of red blood cells. This targeted approach also represents a shift toward mechanism-based therapies in hematology, where drugs are also designed to modify specific molecular pathways linked to inherited blood disorders. The increasing focus on precision medicine and disease-modifying treatments has also encouraged pharmaceutical companies and research institutions to invest in innovative hemoglobin stabilization technologies. In addition, ongoing clinical research exploring combination therapies and long-term treatment benefits is also strengthening physician confidence in these therapies. As healthcare providers increasingly adopt targeted pharmacological strategies for chronic genetic conditions, hemoglobin-modulating drugs such as voxelotor are also gaining stronger clinical and commercial relevance in the evolving sickle cell treatment landscape.
02

Restraint: Global market withdrawal and unfavorable safety profile reducing physician confidence and prescriptions

One of the most critical restraints affecting the voxelotor market is the global withdrawal of the drug due to emerging safety concerns and an unfavorable benefit-risk profile. In September 2024, the manufacturer voluntarily withdrew all lots of voxelotor (Oxbryta) from worldwide markets and discontinued clinical trials after new data indicated that its benefits no longer outweighed the risks for sickle cell disease patients. The safety review highlighted increased occurrences of vaso-occlusive crises and higher mortality rates in certain clinical studies. This decision has significantly disrupted the market by eliminating new prescriptions, halting distribution channels, and forcing healthcare providers to transition patients to alternative therapies. The withdrawal not only reduced immediate drug sales but also weakened investor confidence and slowed further research investments in hemoglobin-modulating therapies.
03

Opportunity: Growing demand for targeted rare disease therapies in emerging pharmaceutical markets and Expanding sickle cell screening programs in African healthcare systems

Emerging pharmaceutical markets are showing increasing demand for targeted therapies addressing rare genetic diseases such as sickle cell disorder. Rising healthcare expenditure, improving diagnostic capabilities, and stronger regulatory support for orphan drugs are enabling wider access to specialized treatments. Countries in the Middle East, Latin America, and parts of Asia are strengthening rare disease treatment frameworks and expanding access to innovative hematology therapies. The oral hemoglobin modulator treatment segment is expected to experience the fastest growth as healthcare providers seek convenient long term treatment options that can improve hemoglobin levels and reduce disease related complications in sickle cell patients.
Growing national screening initiatives for sickle cell disease in African countries present a significant opportunity for the voxelotor market. Many governments and international health organizations are expanding newborn screening programs to improve early detection of genetic blood disorders. Early diagnosis increases the number of patients eligible for disease modifying therapies and supports timely clinical intervention. Countries such as Nigeria and Ghana are strengthening specialized hematology care infrastructure, which can improve treatment adoption. The pediatric sickle cell treatment segment is expected to grow the most as early diagnosis programs enable physicians to introduce advanced therapies earlier in disease management.
04

Challenge: Regulatory suspensions and insurance coverage termination restricting market access and demand

Another major restraint impacting voxelotor market expansion is regulatory suspension and the resulting loss of reimbursement support. Following safety concerns, regulatory agencies such as the European Medicines Agency suspended the marketing authorization for voxelotor while reviewing emerging clinical data. Such actions directly limit the drug’s commercial availability and delay any future relaunch efforts. Additionally, once the drug lost regulatory approval, health insurers and healthcare systems stopped covering voxelotor prescriptions because it was no longer an authorized treatment. This immediately reduced patient access and demand, as physicians shifted to alternative therapies like hydroxyurea or other approved sickle cell treatments. These regulatory barriers and reimbursement disruptions significantly weaken market revenue potential and create long-term uncertainty for companies investing in similar sickle cell disease therapies.

Supply Chain Landscape

1

Active Pharmaceutical Ingredient (API) Production

CambrexThermo Fisher Scientific
2

Drug Formulation & Development

PfizerAstraZeneca
3

Clinical Trials & Regulatory approval

IQVIAPPD
4

Distribution & End Users

Walmart PharmacyCVS Health
Voxelotor - Supply Chain

Use Cases of Voxelotor in Sickle Cell Disease Treatment & Clinical Trials

Sickle Cell Disease Treatment : Voxelotor is primarily used in the treatment of sickle cell disease, where it functions as a hemoglobin modulator that improves oxygen binding and reduces red blood cell sickling. In this application, the oral tablet form of voxelotor is widely utilized because it allows convenient long term management for patients with chronic SCD. By stabilizing hemoglobin in its oxygenated state, voxelotor helps reduce hemolysis and improve hemoglobin levels, which can lower complications associated with anemia and organ damage. Its use is particularly valuable in patients who require continuous disease management beyond traditional therapies such as hydroxyurea. Clinicians often prescribe voxelotor as part of a broader therapeutic strategy aimed at improving quality of life and reducing hospitalization rates in individuals living with sickle cell disease.
Pharmaceutical Sector : Within the pharmaceutical sector, voxelotor plays a significant role as a specialized therapy in the rare disease and hematology drug portfolio. Pharmaceutical companies focus on developing and distributing voxelotor primarily in oral solid dosage form, which supports patient adherence and simplifies treatment administration. The drug’s targeted mechanism of action has positioned it as an innovative therapy in the sickle cell treatment landscape, encouraging pharmaceutical firms to expand research into hemoglobin modifying therapies. Its commercial presence also highlights the growing importance of precision medicine approaches in treating genetic blood disorders. Companies operating in this sector invest in manufacturing optimization, regulatory approvals, and global market access strategies to ensure consistent supply and expand availability of voxelotor based treatments in both developed and emerging healthcare markets.
Clinical Trials : Clinical trials represent another important application area for voxelotor, particularly in ongoing research aimed at expanding its therapeutic potential and improving treatment outcomes for sickle cell disease. In these studies, the oral formulation of voxelotor is commonly evaluated to assess its effectiveness in improving hemoglobin levels, reducing hemolysis markers, and lowering disease related complications. Clinical researchers explore different dosing strategies, combination therapies, and long term safety outcomes to enhance understanding of its benefits in diverse patient populations. Trials also focus on pediatric and adolescent patient groups to evaluate early intervention benefits. The clinical trial environment provides valuable data that supports regulatory approvals, informs treatment guidelines, and helps pharmaceutical developers refine next generation therapies targeting hemoglobin related disorders.

Recent Developments

Recent developments in the voxelotor market reflect significant strategic disruption in the sickle cell disease therapeutics segment. In 2024, the manufacturer Pfizer voluntarily withdrew the drug globally and discontinued ongoing clinical trials after new safety data indicated that the treatment’s benefit no longer outweighed its risks. This action reshaped the competitive landscape for hemoglobin modulator therapies, pushing healthcare providers to shift toward alternative disease-modifying treatments and emerging gene therapy approaches. The key market trend now centers on accelerated innovation in curative and next-generation genetic blood disorder drugs, as pharmaceutical companies intensify R&D investment to address unmet needs in sickle cell disease management.

September 2025 : Pfizer continued regulatory engagement with global agencies and published additional analyses of clinical and real-world data related to Oxbryta following the 2024 withdrawal, as part of its post-market evaluation and safety review process.
September 2024 : Pfizer voluntarily withdrew all lots of Oxbryta from global markets and discontinued all ongoing clinical trials and expanded access programs due to emerging safety concerns and an unfavorable benefit-risk profile.

Impact of Industry Transitions on the Voxelotor Market

As a core segment of the Pharmaceutical industry, the Voxelotor market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Conventional Symptom Management to Targeted Hemoglobin Modulation Therapies and Transition toward Advanced Genetic and Curative Therapies in Sickle Cell Treatment have redefined priorities across the Pharmaceutical sector, influencing how the Voxelotor market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Conventional Symptom Management to Targeted Hemoglobin Modulation Therapies

The introduction of voxelotor marked an important transition in the sickle cell disease treatment landscape, shifting the focus from conventional symptom management to targeted hemoglobin modulation therapies. Traditional treatments such as pain management drugs and hydroxyurea primarily aimed to reduce symptoms or complications rather than directly modifying hemoglobin behavior. Voxelotor introduced a mechanism designed to improve hemoglobin function and reduce red blood cell sickling, encouraging the broader pharmaceutical industry to explore therapies that target underlying disease pathways. This transition has influenced research investment across the hematology sector, with biotechnology companies developing next generation hemoglobin stabilizers and gene-based treatments. In addition, diagnostic companies and specialized hematology clinics have expanded testing and treatment programs, strengthening the overall ecosystem for precision therapies in genetic blood disorders.
02

Transition toward Advanced Genetic and Curative Therapies in Sickle Cell Treatment

Another major transition shaping the voxelotor market is the growing movement toward advanced genetic and potentially curative therapies for sickle cell disease. With rapid advancements in gene editing technologies and stem cell therapies, healthcare providers and pharmaceutical companies are increasingly focusing on long term disease modification rather than continuous pharmacological management. This shift is influencing investment priorities within the biotechnology industry, where firms are allocating significant resources to gene therapy platforms and CRISPR based treatments. For example, companies developing gene therapies are forming partnerships with specialized treatment centers to expand clinical trials and treatment access. As a result, demand patterns in the hematology drug market are gradually evolving, affecting companies involved in conventional sickle cell therapies while encouraging innovation across the broader rare disease and genetic medicine industries.